Thomas Powles
托马斯·鲍尔斯
MBBS, MRCP, MD
Professor of Genitourinary Oncology; Director, Barts Cancer Centre泌尿肿瘤学教授；巴茨癌症中心主任
👥Biography 个人简介
Thomas Powles, MBBS MRCP MD is Professor of Genitourinary Oncology and Director of Barts Cancer Centre at Queen Mary University of London. He is one of Europe's most prolific IO trial leaders in kidney and urothelial cancers, having contributed to multiple nivolumab-based combination trials in advanced RCC and led landmark urothelial cancer studies. He is a key author of ESMO RCC clinical practice guidelines and a global thought leader in genitourinary oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Nivolumab Combinations in Advanced RCC
Led and co-led multiple nivolumab-based combination trials in advanced renal cell carcinoma across European cooperative groups, contributing pivotal phase II/III data that supported regulatory approvals and informed ESMO guideline updates for first-line RCC treatment.
ESMO Renal Cell Carcinoma Clinical Practice Guidelines
Served as lead or co-lead author on multiple versions of the ESMO clinical practice guidelines for RCC, synthesizing global trial data into evidence-based treatment algorithms adopted by oncologists across Europe and internationally.
IO Biomarker and Translational Research in Genitourinary Cancers
Conducted extensive translational research characterizing tumor microenvironment, PD-L1 expression, and genomic predictors of checkpoint inhibitor response in RCC and urothelial carcinoma, informing patient stratification in both diseases.
Representative Works 代表性著作
ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up: Renal Cell Carcinoma
Annals of Oncology (2021)
Comprehensive ESMO guideline providing evidence-based recommendations for advanced RCC management, widely adopted across Europe as the primary reference for IO-based combination treatment decisions.
Durvalumab and Tremelimumab Alone or in Combination in Previously Untreated Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Journal of Clinical Oncology (2020)
Phase II trial investigating dual checkpoint blockade in advanced urothelial carcinoma, generating data that informs both UC and RCC IO combination development strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 托马斯·鲍尔斯 的研究动态
Follow Thomas Powles's research updates
留下邮箱，当我们发布与 Thomas Powles（Barts Cancer Institute, Queen Mary University of London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment